Skip to main content

Table 2 Subgroup Analysis in proportion of relapse free patients

From: Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis

Subgroups (no. of studies)
 Study type Effect size (95% C.I.) I2 Subgroup difference
 Observational Study (6) 68.6% (95% CI: 0.44–0.94), p < 0.001 82.69% 0.19
 Randomized Controlled Trial (1) 86.4% (95% CI: 0.78–0.95), p < 0.001 NA
Duration of follow-up
  < 20 months (3) 73.9% (95% CI:0.49–0.98), p < 0.001 53.54% 0.94
  > 20 months (3) 70.8% (95% CI:0.33–1.09), p < 0.001 89.55%
Percentage of AQP-4 positivity
 All (100%) (4) 64.6% (95% CI:0.27–1.02), p = 0.001 86.32% 0.31
 Not All (100%) (3) 84.3% (95% CI: 0.76–0.92), p < 0.001 0%
Site of Injection
 Intravenous (5) 67.1% (95% CI:0.45–0.89), p < 0.001 64.68% p = 0.001
 Subcutaneous (1) 100% (95% CI:0.98–1.02), p < 0.001 NA
 Mixed (1) 66.7% (95% CI:0.40–0.93), p < 0.001 NA